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Abstract
Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy generally associated with poor prognosis.
Allogeneic hematopoietic cell transplantation (alloHCT) continues to be the most potent anti-leukemia treatment for adult
patients with intermediate and high-risk AML. However, disease relapse after alloHCT remains unacceptably high and is the
primary cause of treatment failure and mortality following alloHCT. It is therefore that post-transplant early cellular or
pharmacologic maintenance or preemptive strategies to enhance the graft-versus-leukemia effect or to eradicate persistent
minimal residual disease have been of renewed interest, particularly with the availability of more sensitive technologies to
measure residual AML. Although preliminary studies have demonstrated improved outcomes with the use of post-alloHCT
remission therapies, prospective randomized trials are required to determine their clinical efﬁcacy and role in the treatment of
AML. On behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we
summarize the available evidence on the use and efﬁcacy of available pharmacologic post-remission therapies, including
hypomethylating agents, deacetylase inhibitors, and tyrosine kinase inhibitors, as well as cellular therapies, including
preemptive and prophylactic donor lymphocyte infusions for the prevention of relapse of AML.
Introduction
Over the past decade, the international blood and marrow
transplantation (BMT) community have witnessed sig-
niﬁcant therapeutic advances in allogeneic hematopoietic
cell transplantation (alloHCT) for acute myeloid leukemia
(AML). Development of improved supportive care,
reduced-intensity conditioning (RIC) regimens, thereby
extending transplants to adults age 60 and older and/or with
co-morbidities, and transplant procedures using alternative
donors and stem cell sources have resulted in 3–5-year
overall survival (OS) rates ranging from 20 to 90%,
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depending on the AML risk proﬁle and stage and the pre-
sence or absence of minimal residual disease (MRD) [1–3].
However, disease relapse accounts for ~ 40% of treatment
failures, with a preponderance of failures occurring in the
ﬁrst year following alloHCT [4]. Therapeutic options for
post-transplant relapse include best supportive care, rapid
withdrawal of immunosuppression, low or high-intensity
chemotherapy followed by cellular immunotherapy, such as
a second transplantation in selected cases or donor lym-
phocyte infusions (DLI). However, outcomes following
these salvage treatments are generally poor [4, 5]. Several
studies have also shown worse survival among patients with
early relapse ( < 6 months) from time after alloHCT [4–6],
leading to stronger rationale for early prevention strategies.
Increasing understanding of the immune-biology and
molecular landscape of AML has resulted in targeted and
other biologically directed therapies against minimal resi-
dual tumor burden while providing immunomodulatory
support for the graft-versus-leukemia (GVL) effect by
enhancing allogeneic immune responses. In addition,
knowledge of pre-transplant parameters associated with a
high relapse risk such as high-risk karyotype and/or muta-
tions and molecular markers, advanced disease stage, or the
presence of MRD has allowed selection of patients who
would beneﬁt most from post-remission prevention strate-
gies. As older age in itself may be a risk factor for relapse,
patients age ≥ 60 may also qualify for post-transplantation
maintenance therapy. Other factors associated with a greater
risk of AML relapse in the post-transplantation setting are
related to the presence of pre-transplant or post-transplant
MRD, RIC regimens, the absence of chronic GVHD
(cGVHD), loss of donor chimerism, use of in vivo or
ex vivo T-cell-depleting mechanisms, and although con-
troversial, high-dose post-transplant cyclophosphamide
(PTCy) for the prevention of GVHD [7, 8]. The on-going
study BMT CTN 1301 (NCT02345850) that randomizes
recipients of HLA-matched related and unrelated donor
transplantation to three prophylaxis strategies for GVHD,
two being infusion of bone marrow grafts followed by
either PTCy or standard calcineurin inhibitor-based regi-
men, may better elucidate the effect of PTCy on disease
relapse. At last, the development of more sensitive tech-
nologies continues to change our ability to measure
remaining disease burden following alloHCT and allows
direct evaluation of the efﬁcacy of a speciﬁc post-remission
treatment. This evolution has led to a new wave of active
investigation into the role of post-remission maintenance or
preemptive therapies to mitigate the risk of AML relapse
following alloHCT. As several of these agents also have
activity in myelodysplastic syndrome (MDS), we discuss
the available and potential candidate therapies for preven-
tion of relapse of AML and MDS in the post- transplanta-
tion setting.
Maintenance vs. preemptive strategies to
prevent relapse
Maintenance treatments may be an effective strategy to
provide early tumor control and immunomodulatory sup-
port for the GVL effect provided by allogeneic immune
responses in patients with high-risk AML. However, for
patients with intermediate-risk AML, maintenance therapies
may represent over-treatment and expose patients who are
cured of their disease to adverse long-term and late effects
of therapy. Therefore, preemptive treatment strategies that
employ monitoring for MRD after transplantation by use of
ﬂow cytometry, cytogenetic, or molecular assays, may
avoid unnecessary treatment exposures while achieving
similar success in preventing morphologic relapse. Prior to
the advent of novel pharmacologic and cellular treatments,
early withdrawal of immune suppression with or without
prophylactic DLI were considered. However, these inter-
ventions have been limited by the development of sig-
niﬁcant GVHD and marrow aplasia, and in the setting of
DLI, has limited activity outside of chronic myeloid leu-
kemia (CML) [9, 10]. The development of epigenetic
therapies that have the ability to expand T regulatory cells
has led to renewed interest in evaluating the efﬁcacy of
concurrent administration with DLI for prevention of
relapse in AML [11].
Hypomethylating agents
The hypomethylating agents, azacitidine and decitabine,
reverse DNA hypermethylation employed by tumor cells to
inhibit genes responsible for growth inhibition, differentia-
tion, and apoptosis of cancer cells. Other mechanisms of
hypomethylating agents include cytoreductive and pro-
differentiation effects on leukemic cells [12]. Both azaciti-
dine and decitabine have demonstrated meaningful clinical
activity in front-line therapy for AML and MDS in older
patients unable to tolerate intensive chemotherapy [13, 14].
In the transplant setting, azacitidine and decitabine may
augment the GVL response through upregulation and re-
expression of epigenetically silenced genes related to major
histocompatibility complex class I, human leukocyte anti-
gen DR-1 and tumor-associated antigens [15]. CD8 T-cell
responses against tumor antigens are augmented by these
changes [16] and also in part by increased expression of
killer-cell immunoglobulin-like receptor on T cells [17]. In
the setting of relapsed AML following allogeneic trans-
plantation, low-dose azacitidine has shown favorable anti-
leukemia activity and toxicity proﬁle without exacerbating
GVHD [18–22]. Subsequent research using murine models
showed that immunomodulation of GVHD without the loss
of GVL may result from expansion of regulatory T cells
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exerted by azacitidine and decitabine [15, 16, 23, 24].
Collectively, these studies have laid rationale to examine
the safety and efﬁcacy of hypomethylating agents following
alloHCT for the prevention of AML/MDS recurrence.
Azacitidine
Azacitidine has been the most extensively studied for this
indication. Investigators at MD Anderson Cancer Center
were the ﬁrst to suggest efﬁcacy for post-transplant azaci-
tidine based on a retrospective case series of patients treated
at their center [18].
A follow-up phase I dose-ﬁnding study of low-dose
azacitidine following RIC alloHCT for 45 patients with
AML/high-risk MDS in CR1 or greater demonstrated that
azacitidine can be safely administered to heavily pretreated
post-transplant patients [25]. A total of 45 patients (AML, n
= 37; MDS, n= 8) with median age of 60 years who were
in complete remission (CR) by day 30 following alloHCT
received subcutaneous azacitidine starting at day+ 40 post
transplantation. The investigators deﬁned a maintenance
regimen of 32 mg/m2/day, days 1–5 every 30 days, for four
cycles as optimal. With a median follow-up time of
20.5 months (range, 7.7–39.6 months), 24 patients (53%)
developed disease recurrence, with 7 recurrences occurring
while on azacitidine. Nineteen (42%) patients died at a
median of 30.8 months (95% conﬁdence interval (CI), 14.3
months-upper limit not estimable) and 15 of these deaths
were attributed to disease recurrence. One-year event-free
survival and OS were 58 and 77%, and whereas deﬁnite
associations between acute GVHD (aGVHD) and azaciti-
dine administration could not be determined, cGVHD may
have been diminished with longer schedules of azacitidine
[25]. At present, a phase III randomized controlled study
comparing 1-year of azacitidine maintenance therapy (32
mg/m2/d for 5 days every 28 days) vs. no maintenance for
prevention of relapse after alloHCT in patients with inter-
mediate or high-risk AML/MDS is ongoing
(NCT00887068).
In a single-arm, non-randomized, phase II study of
maintenance azacitidine following RIC alloHCT for AML
(RICAZA), Craddock et al. [26] reported on the safety and
tolerability of subcutaneous azacitidine 36 mg/m2 on days
1–5 every 28 days beginning on day+ 42 after alloHCT for
up to 12 months after transplantation in 37 patients. A
preliminary analysis focused on biological parameters in the
ﬁrst 27 enrolled patients was reported by Goodyear et al.
[16]. In the updated analysis, the median follow-up time
was 24 months and 31 patients completed at least three
cycles of azacitidine, whereas 16 (50%) patients completed
10 cycles. Sixteen patients relapsed at a median time of
8 months after transplantation, and a total of 19 (51%)
deaths occurred with disease relapse as the cause in 16
(84%) cases. The 1-year and 2-year OS were 81% (95% CI,
69–95%) and 49% (95% CI, 35–68%), respectively. Grade
3–4 aGVHD did not occur during treatment with azacitidine
and there were no cases of extensive cGVHD. Azacitidine
was generally well-tolerated in the majority of patients.
Correlative studies showed an association between induc-
tion of peripheral blood antitumor CD8+ T-cell responses to
one or more tumor-speciﬁc peptides in azacitidine-treated
patients with a decrease in relapse risk (HR, 0.30; 95% CI,
0.10–0.85; P= 0.02) and improved relapse-free survival
(RFS) (HR, 0.30; 95% CI, 0.1–0.94; P= 0.039). The ability
of azacitidine to induce CD8+ tumor-speciﬁc T-cell
responses, coupled with the expansion of T regulatory
cells, support the notion that adjunctive administration of
therapies that epigenetically modify the GVL effect without
enhancing GVHD following transplantation is a feasible
and rationale therapy.
Owing to the potential immunomodulatory effects of
azacitidine in the post-transplantation setting, Platzbecker
et al. [27] prospectively administered azacitidine to patients
as preemptive treatment for prevention of AML/MDS
relapse based on MRD as determined by decreasing CD34+
donor chimerism ( < 80%) analysis (RELAZA study).
Twenty patients with MRD+ hematologic remission fol-
lowing alloHCT received four cycles of azacitidine at 75
mg/m2/day for 7 days. An improvement in donor chimerism
to ≥ 80% or stabilization of chimerism was observed in 80%
of patients. Eleven patients with stable chimerism or sub-
sequent decrease to < 80% after the initial response received
a median of four additional cycles. Although hematologic
relapse occurred in 13 patients (65%), this was delayed until
a median of 231 days (range, 56–558) from the initial
decrease of CD34+ donor chimerism. Similarly, the German
Cooperative Transplant Study Group also reported out-
comes of their retrospective multicenter analysis of 154
patients with AML (n= 124), MDS (n= 28), and myelo-
proliferative syndromes (n= 2) who had hematologic or
molecular relapse of disease and were treated with a median
number of four cycles of azacitidine and planned DLI [21].
Although the complete remission rate was 27% and 2-year
OS was 29% for the entire group, those who were treated
with molecular-only relapse had better OS (HR, 0.14; 95%
CI, 0.03–0.59; P= 0.007). Results from this study and
RELAZA demonstrate the feasibility of preemptive use of
azacitidine in the setting of MRD and warrant further pro-
spective study.
Oral azacitidine
The epigenetic modiﬁer CC-486 is an oral formulation of
azacitidine with promising clinical activity in patients with
high-risk AML/MDS in Phase I/II studies. Extended aza-
citidine dosing with sustained DNA hypomethylation over a
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treatment course and long-term treatment with oral admin-
istration of azacitidine have the potential to enhance
demethylation among cycling malignant cells, translating to
improved clinical outcomes. Final results from the QUA-
ZAR phase I/II multicenter dose and schedule ﬁnding study
of oral azacitidine as maintenance therapy after reduced-
intensity or myeloablative alloHCT for AML/MDS were
reported [28]. Treatment with one of four daily dosing
schedules (CC-486 200 mg or 300 mg for 7 days, 150 mg or
200 mg for 14 days) in repeated 28-day cycles was started
between day+ 42 and day+ 84 after alloHCT. Thirty
evaluable patients (AML, n= 26; MDS, n= 4) were
included. The maximum tolerated dose (MTD) was not
reached and the CC-486 200 mg daily for 14 days dosing
was additionally assessed. Ten of nineteen patients (53%)
completed all 12 treatment cycles, and with a median
follow-up for all patients of 19.0 months (range 1.0–41.3), 8
of 30 patients (27%) had relapsed or progressive disease.
The median relapse- and progression-free survival (RPFS)
for all patients was 34.1 months (95% CI 15.3, 37.8),
whereas median RPFS and median OS were not reached in
the combined 14-day dosing groups. One-year RPFS and
OS in the 14-day dosing cohorts were 72% and 81%,
respectively. The most common grade 3–4 treatment
emergent adverse events were related to gastrointestinal and
hematologic parameters, and two of eight patients experi-
enced severe cGVHD. A randomized, phase III trial eval-
uating CC-486 at the 200 mg 14-day dosing regimen as
maintenance therapy following transplantation for high-risk
MDS and intermediate- or high-risk AML is in
development.
Decitabine
A dose-escalation and safety study of decitabine as main-
tenance therapy after reduced-intensity or myeloablative
allogeneic transplantation for AML/MDS was reported by
Pusic et al. [29]. Four decitabine doses (5, 7.5, 10, and 15
mg/m2/day) given on days 1–5 in 6-week cycles for up to
eight cycles were investigated in cohorts of four patients
among 22 AML/MDS (AML, n= 17; MDS, n= 5) patients
in CR after alloHCT to determine the MTD. Treatment
began between day+ 50 and day+ 100 after transplanta-
tion. All four-dose levels were completed and the MTD was
not reached; however, the authors concluded that a dose of
10 mg/m2 for 5 days every 6 weeks was optimal owing to
minimal hematological toxicity. Nine of 22 (41%) patients
completed eight cycles (median number of cycles com-
pleted= 5) and all were alive at the time of the report, with
eight of the nine patients remaining in CR. After a median
follow-up of 26.7 months (range, 3.4–49.1), six patients
relapsed and nine died (four from relapse, three from
infections, and two owing to GVHD). The 2-year OS and
disease-free survival were 56% (95% CI, 38–83%) and 48%
(95% CI, 30–75%), respectively. The 2-year cumulative
incidence (CI) of relapse was 28% (95% CI, 8–48%).
Decitabine did not seem to inﬂuence the incidence of
cGVHD and its effect on aGVHD was uncertain owing to
the timing of its administration. A correlative study showed
a trend for increased FOXP3 expression and Treg cells
among the lymphocyte population, but it was not statisti-
cally signiﬁcant.
Additional studies evaluating azacitidine or decitabine as
monotherapy or in combination with other therapies for
prevention of relapse in high-risk AML/MDS following
alloHCT are summarized (Table 1).
Histone deacetylase and hedgehog
inihibitors
The class I/II histone deacetylase inhibitors (HDACi) have
been explored as potential therapeutic agents in AML/MDS
owing to marked induction effects on cell-cycle arrest, cell
differentiation, and pro-apoptotic effects on AML cells
through epigenetic modiﬁcations of nucleosome histones.
HDACis have also been reported to affect both immune-
suppressive and immune-stimulating responses through the
modulation of cytokine expression [30, 31].
Panobinostat (PAN) is an oral, highly potent, and non-
selective HDACi reported to have moderate anti-leukemia
activity in a small subset of patients with advanced AML
and high-risk MDS in early phase studies [32]. It also
inhibits the suppressive function of regulatory T cells at low
doses while promoting its inhibitory function at higher
doses [30], and therefore, may have potential in mitigating
GVHD. Using this rationale, Bug et al. [33] investigated
PAN as maintenance therapy for patients with high-risk
MDS/AML in hematologic CR following RIC alloHCT
(PANOBEST). In this phase I/II study of 42 patients
(median age, 52), the majority of whom were transplanted
with active disease (67%), PAN was administered within
60–150 days after alloHCT and continued for up to 1-year.
The phase 1 portion of the trial identiﬁed the MTD and
dose-limiting toxicity (DLT) of two sequentially tested
dosing schedules. In phase II, patients were randomized 1:1
to either schedule at the respective MTD. Phase I results on
23 out of 24 evaluable patients showed a recommended
phase 2 dosing of 20 mg TIW for schedule A and 30 mg
TIW every other week for schedule B.
In the phase II study, safety analysis on all patients
showed that 35 of 42 patients (83%) experienced at least
one grade 3–4 adverse events, most of them related to
hematologic toxicity, constitutional symptoms, and gaster-
ointestinal symptoms. There were no patient deaths while
on treatment or within 28 days of the last PAN dose. More
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than half of the patients completed 1-year of treatment with
PAN (n= 22). The median treatment duration at the MTD
was 52 days (range, 11–368) in schedule A vs. 228 days
(range, 16–365) in schedule B. Although DLIs were per-
mitted by the study protocol, this did not translate to a
signiﬁcantly higher incidence of GVHD. Only four of 42
patients developed aGVHD and the CI of moderate/severe
cGVHD was 29% (95% CI, 16–42%) at 2 years after
starting PAN. There was no difference in cGVHD between
the two schedule cohorts and all patients with aGVHD
received schedule A dosing. After a median follow-up of
22 months, the median OS and RFS had not been reached
and the estimated 2-year OS and RFS were 81% (95% CI,
69–95%) and 75% (95% CI, 63–90%), respectively. Non-
relapse mortality (NRM) was also low at 5% (95% CI,
0–11%). Owing to the favorable outcomes demonstrated in
this study compared with reported survival and relapse rates
of similar patient groups, a large European randomized trial
to formally test maintenance PAN following alloHCT for
high-risk myeloid malignancies is planned [33].
Aberrant hedgehog (Hh) pathway signaling has been
hypothesized to contribute to the survival and expansion of
leukemia stem cells, and accordingly, the use of an Hh
inhibitor can eliminate these cells and decrease relapse rates
[34]. The smoothened receptor inhibitor PF-04449913
(glasdegib), an Hh inhibitor, has recently shown
promising results in a randomized phase II trial, prolonging
median OS by ~ 3 months when combined with low-dose
cytarabine (LDAC) as compared to LDAC alone in AML/
MDS patients ineligible for intensive chemotherapy [35].
With this background, use of PF-04449913 is under
investigation in a phase II study as a maintenance agent
following alloHCT for patients at high-risk of relapse
(NCT01841333).
Inhibitors of ﬂt3 tyrosine kinase
Activating mutations of the FMS-like tyrosine kinase 3
(FLT3) receptor are present in ~ 30% of patients with
newly diagnosed AML and are associated with an overall
poor prognosis [36]. FLT3-internal tandem duplications
(ITD) of exons 13–15, coding for the juxtamembrane of
FLT3 receptor region are the most frequent genetic aber-
rations and are found in 23% of de novo AML [36].
Mutations in FLT3-ITD confer downstream signaling
pathways involving STAT5, PI-3-kinase/AKT, and RAS/
MAPK, leading to abnormal leukemia cell growth, differ-
entiation, and survival [37, 38]. Other contributing factors
to unfavorable outcomes are the presence of high FLT3
mutant allelic burden as compared with patients with low
or intermediate allelic ratios [39], long ITD length [40],
Table 1 Ongoing studies using epigenetic and immunomodulatory agents as maintenance or preemptive therapy for high-risk AML/MDS
following allogeneic hematopoietic cell transplantation
Drug Active clinical trials
Azacitidine Phase II study to determine the 2-year PFS of SC or IV azacitidine when started on Day+ 42 and given days 1–5 every
4 weeks for six cycles after RIC alloHCT conditioned with Fludarabine, Busulfan, and ATG. Secondary outcomes include
rate of aGVHD and cGVHD; 100-day and 1-year TRM, 5- year OS (NCT01168219).
Phase II study to determine the 2-year relapse rates of SC azacitidine 32 mg/m2 daily for 5 days of a 28-day cycle starting
between days 60 and 120 post TCD alloHCT and up to a year. Secondary outcomes include 2-year OS and safety)
(NCT01995578).
Phase II study combining SC or IV azacitidine 40 mg/m2 daily for 5 days with valproic acid 15 mg/kg daily, days 6–28, for
up to four total cycles to determine the 1-year OS. Secondary outcomes include PFS, relapse, and toxicity (NCT02124174).
Phase II study of SC or IV azacitidine 40 mg/m2 with and without DLI based upon disease risk to determine 2-year relapse
rate, grade 3 or higher adverse events and aGVHD and cGVHD in pediatric and young adults with acute leukemia
(NCT02458235).
Randomized phase 3 trial to determine whether SC azacitidine 32 mg/m2 daily for 5 days up to 12 cycles provides at
minimum a 50% improvement in median RFS at 3, 6, and 12 months (NCT00887068).
Decitabine Phase I study to determine dose and schedule ﬁnding of decitabine 5 mg/kg/day to 15 mg/kg/day IV daily for 5 days up to
12 cycles beginning at days 42–90 after alloHCT. Secondary outcomes include OS and RFS; donor chimerism, GVHD;
biomarkers of immune recovery (NCT01277484).
Lenalidomide Phase II study to determine RFS of oral lenalidomide starting at a dose of 10 mg daily, days 1–28, for high-risk AML in
remission after alloHCT (NCT02126553).
Hedgehog inhibitor
(PF-04449913)
Phase II study to determine 1-year RFS of oral PF-04449913 dosed at 100 mg daily, days 1–28, for up to 12 cycles.
Secondary outcomes include OS, remission duration, and toxicity (NCT01841333).
aGVHD acute graft-versus-host disease, alloHCT allogeneic hematopoietic cell transplantation, AML acute myeloid leukemia, ATG anti-thymocyte
globulins, cGVHD chronic graft-versus-host disease, CI cumulative incidence, CR complete remission, DFS disease-free survival, DLI donor
lymphocyte infusion, EFS event-free survival, IV intravaneous, LFS leukemia-free survival, MRD minimal residual disease, NGS next-generation
sequencing, NRM non-relapse mortality, OS overall survival, PFS progression-free survival, RFS relapse-free survival, SC subcutaneous, SOC
standard-of-care, TCD T-cell depleted, TRM transplant-related mortality
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and the location of the insertion site within the tyrosine
kinase domain [39].
As multiple studies indicate AML harboring a FLT3-ITD
mutation is a poor prognostic marker for relapse and sur-
vival in patients receiving chemotherapy alone [41–43],
alloHCT has been widely recommended by expert panels as
post-remission consolidation treatment for patients in ﬁrst
CR [44]. Despite the reported beneﬁt conferred by alloHCT
for FLT3-ITD AML, the literature also suggests that early
relapse after transplant remains a threat for patients with
FLT3-ITD AML as compared with other AML subtypes
[36, 45, 46]. Therefore, for many patients, the current
standard-of care consisting of induction chemotherapy fol-
lowed by post-remission consolidation with alloHCT is
inadequate. It has been postulated that FLT3-ITD AML
originates as a polyclonal disease at diagnosis and can be
successfully suppressed by conventional chemotherapy and
intense post-remission therapy, however, clonal evolution
may produce a dominant FLT3-dependent clone at the time
of relapse for, which targeted therapy is necessary [47].
With this rationale, several small molecules capable of
inhibiting FLT3 tyrosine kinase activity have been devel-
oped and evaluated for use in the induction-remission,
relapsed/refractory, and post-alloHCT setting. The para-
digm of maintenance therapy following alloHCT for AML
has garnered renewed interest, as reports of decreased
incidence of relapses and improved outcomes with pro-
phylactic use of BCR-ABL tyrosine kinase inhibitors (TKIs)
following alloHCT for patients with high-risk CML or Ph
+ acute lymphocytic leukemia [48, 49]. In addition, FLT3
inhibitors may function similarly to BCR-ABL TKIs and not
only directly target residual leukemia cells but also syner-
gize with allo-reactive donor cells and augment the GVL
response [50]. Therefore, we summarize current ongoing
clinical trials of various FLT3 inhibitors under evaluation as
maintenance therapy following alloHCT (Table 2).
Sorafenib
Sorafenib is a small inhibitor of several tyrosine protein
kinases, such as FLT3-ITD, RAF kinase, PDGFR, VEGFR,
c-KIT, and others [51]. As sorafenib demonstrated some
clinical activity in the post-transplant relapsed setting [52,
53], the research focus shifted to determining its value for
prevention of relapse following alloHCT. The data sup-
porting sorafenib as post-transplantation maintenance ther-
apy are based upon single-arm studies or retrospective
reports. Chen et al. [54] reported results of the ﬁrst phase I
trial using sorafenib as maintenance therapy following
transplantation for any patient with FLT3-ITD AML in CR
after transplantation. Sorafenib was administered to 22
patients beginning between days 45 and 120 after ﬁrst
Table 2 Ongoing studies using FLT3 inhibitors as maintenance therapy for FLT3-ITD AML following allogeneic hematopoietic cell
transplantation
FLT3 inhibitor Active clinical trials
Sorafenib Pilot study evaluating the safety of sorafenib before and after alloHCT for patients with FLT3-ITD AML. Secondary outcomes
include CI NRM, and relapse, DFS, OS, change in FLT3 inhibition and MRD by ﬂow cytometry (NCT01578109).
Phase II study evaluating sorafenib vs. placebo as post-alloHCT maintenance therapy on 42-month RFS in patients with FLT3-
ITD AML. Secondary outcomes include median OS, median RFS, and OS according to NPM1 status, median RFS, and OS
according to baseline FLT3-ITD allelic burden, safety and toxicity, and biomarker assessments (EudraCT 2010-018539-16)
Phase II/III study evaluating sorafenib maintenance therapy vs. usual SOC following alloHCT on the incidence of leukemia
relapse in FLT3-ITD AML. Secondary outcomes include OS, LFS, and safety (NCT02474290).
Midostaurin Phase II study evaluating SOC with midostaurin vs. SOC following alloHCT on RFS among patients with FLT3-ITD AML who
undergo alloHCT. Secondary outcomes include DFS, NRM, OS, FLT3-ITD mutation status (i.e., allelic ratio), safety, and
tolerability (NCT01883362).
Phase II study evaluating midostaurin with intensive induction, consolidation including alloHCT, and single-agent maintenance
therapy on EFS in patients with FLT3-ITD AML. Secondary outcomes include CR, RFS, OS, CI relapse, and death in CR, FLT3
inhibition, QoL, and safety (NCT01477606).
Quizartinib Phase III study evaluating quizartinib vs. placebo with standard induction, consolidation chemotherapy with or without
alloHCT, then as maintenance therapy on EFS in patients with FLT3-ITD AML. Secondary outcomes include 2-year OS, rates
of CR and composite CR after the 1st induction cycle, and CR with no MRD (NCT02668653).
Crenolanib Phase II study evaluating crenolanib maintenance therapy following alloHCT for patients with FLT3-ITD AML. Secondary
outcomes include 2-year DFS, OS, and GVHD, and 100-day TRM (NCT02400255).
Gilteritinib Phase III study evaluating gilteritinib maintenance therapy vs. placebo following alloHCT for patients with FLT3-ITD AML on
RFS. Secondary outcomes include OS, EFS, MRD using a novel NGS assay, and safety (BMT CTN 1506; NCT02927262 and
NCT02997202).
alloHCT allogeneic hematopoietic cell transplantation, AML acute myeloid leukemia, CI cumulative incidence, CR complete remission, DFS
disease-free survival, EFS event-free survival, LFS leukemia-free survival, MRD minimal residual disease, NGS next-generation sequencing, NRM
non-relapse mortality, OS overall survival, QoL quality-of-life, RFS relapse-free survival, SOC standard-of-care, TRM transplant-related mortality.
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alloHCT with any donor source, conditioning regimen, and
GVHD prophylaxis and was given continuously in 28-day
cycles for up to 12 cycles. Following a 28-day DLT period,
the MTD was set at 400 mg twice daily. With a median
follow-up for surviving patients of 16.7 months after
alloHCT (range, 8.1–35.0 months), 1-year progression-free
survival (PFS) was 85% (90% CI, 66%-94%) and 1-year
OS was 95% (90% CI, 79–99%). For the cohort of patients
who were in CR1/CR2 prior to HCT (n= 19), 1-year PFS
was 95% (90% CI, 76–99%) and 1-year OS was 100%.
Sorafenib was reasonably well tolerated, with grade 2–3
rash (36%), diarrhea (32%), and anemia (27%) as the most
commonly adverse events reported. Only one patient
developed aGVHD (grade II disease of the skin) after
starting sorafenib maintenance. The CI of cGVHD in the
12 months after starting sorafenib (38%, 90% CI, 21–56%)
was similar to historical controls [54].
This group of investigators further performed a retro-
spective analysis comparing outcomes of consecutive
patients with FLT3-ITD AML who received transplanta-
tion in ﬁrst CR and received sorafenib maintenance (n=
26) vs. those who did not (n= 43) [55]. A landmark
analysis was performed beginning at day 68 after trans-
plantation, as this was the median time to initiation of
sorafenib. Sorafenib maintenance was associated with a
signiﬁcantly superior 2-year OS (81% vs. 62%, P=
0.029), PFS (82% vs. 53%, P= 0.0081), and lower 2-year
CI of relapse (8.2% vs. 37.7%, P= 0.0077). The rates of
NRM or cGVHD were no different between groups.
Meanwhile, other retrospective studies have also reported
encouraging outcomes with the use of sorafenib as post-
alloHCT maintenance therapy [56, 57].
Sorafenib as post-transplant maintenance therapy for FLT3-
ITD AML continues under active investigation across the
world. In the United States, a National Cancer Institute
sponsored study (NCT01578109) has completed accrual for
their prospective trial evaluating the safety and outcomes of
sorafenib administered peri-transplant and as post-transplant
maintenance therapy. Pratz et al. [58] reported preliminary
data on 28 patients with FLT3-ITD AML who underwent
transplantation in CR. With a median duration of post-
transplant follow-up of 450 days (range, 107–1192) and a
median duration of sorafenib therapy of 252 days (range,
52–1081), a total of ﬁve relapses and six deaths occurred
(three due to relapse). Nine patients developed grade 2 or
higher GVHD requiring escalation of immunosuppression
therapy.
The ongoing multicenter European study, SORMAIN
(EudraCT 2010-018539-16), is a phase II, double-blinded,
placebo-controlled, randomized trial to assess the efﬁcacy
of sorafenib maintenance therapy in FLT3-ITD AML in
complete hematological remission after alloHCT. Study
treatment begins at day 60–100 after transplant. Clinical
objectives include determination of RFS, and comparison of
median RFS and OS in FLT3-ITD patients receiving sor-
afenib vs. placebo, accounting for NPM1 mutations and
baseline FLT3-ITD allelic burden. The ﬁnal results of these
prospective studies are eagerly anticipated and should pro-
vide additional evidence regarding tolerability and efﬁcacy
of maintenance sorafenib following alloHCT in patients
with FLT3-ITD AML.
Midostaurin
Midostaurin (PKC412) is a ﬁrst-generation oral multi-
kinase inhibitor of both wild-type and mutated FLT3,
VEGFR2, c-KIT, and PDGFR [59, 60]. It was recently
approved by the US Food and Drug Administration (FDA)
for upfront treatment in combination with chemotherapy for
patients with newly diagnosed FLT3-mutated AML based
on the superior OS and EFS reported in the phase III ran-
domized CALGB 10603/RATIFY trial [61]. Concurrently,
midostaurin is also under investigation as a potential
maintenance therapy following alloHCT to prevent AML
relapse. The RADIUS trial (NCT01883362) is an ongoing
phase II, randomized trial to determine whether the addition
of post-transplant maintenance therapy with midostaurin 50
mg twice daily to standard-of care will reduce relapse fol-
lowing myeloablative alloHCT from a matched related or
unrelated donor in patients with FLT3-ITD AML. In this
study, midostaurin is administered beginning days 28–60
post transplantation, every 28 days for 12 cycles. The pri-
mary study endpoint is RFS determined at 18 months from
date of transplant.
The German-Austrian AMLSG 16-10 trial
(NCT01477606) is currently accruing to their phase II,
single-arm study of midostaurin 50 mg twice daily in
combination with intensive induction, peri-transplant, and
as single-agent maintenance therapy after alloHCT for
patients with FLT3-ITD AML. Preliminary results from
147 patients who underwent induction therapy with
midostaurin and conventional chemotherapy revealed an
overall CR of 75% and death rate of 7.5%. Maintenance
therapy was started in 52 patients (40 patients after
alloHCT and 12 patients after consolidative chemother-
apy). Initial analyses showed a low CI of relapse irre-
spective of the FLT3-ITD allelic burden. Most frequent
grade 3–4 adverse events (AEs) reported during the ﬁrst
induction cycle included gastrointestinal AEs (n= 34)
and infections (n= 81) [62].
Quizartinib
Quizartinib (AC220) is a highly potent, second-generation
receptor tyrosine kinase inhibitor (TKI) developed speciﬁ-
cally as a FLT3 inhibitor. It addition to its speciﬁcity for
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FLT3-ITD, quizartinib is associated with a signiﬁcantly
longer half-life in vivo and has greater duration of FLT3
inhibition than ﬁrst-generation FLT3 inhibitors [63]. Phase
II studies of patients with relapsed/refractory FLT3-ITD
AML showed quizartinib to have a high level of single-
agent activity [64, 65].
Sandmaier et al. [66] reported on the safety of qui-
zartinib maintenance in a phase I, dose-escalation study of
13 patients who achieved CR after a matched alloHCT.
Patients were enrolled into two dose cohorts; 40 mg daily
(n= 7) and 60 mg daily (n= 6), and began maintenance
therapy between days 30 and 60 after transplantation for
up to 24 continuous treatment cycles (28-day cycles). At
the time of the report, 10 patients had received quizartinib
for more than a year, 6 were currently receiving treatment,
and 2 subjects completed 24 cycles. One out of 13 patients
relapsed (after 22 days on study) and three subjects dis-
continued due to AEs including grade 4 neutropenia, grade
2 corneal epithelium defects, and grade 3 autoimmune
hemolysis. Otherwise, toxicities were manageable. Qui-
zartinib maintenance did not appear to increase the rate of
GVHD. At present, the global phase III, randomized and
placebo-controlled study, QuANTUM-First
(NCT02668653), is determining the efﬁcacy of quizarti-
nib as adjunctive therapy to standard induction and con-
solidation chemotherapy followed by single-agent
maintenance therapy on survival outcomes in newly
diagnosed patients with FLT3-ITD AML. Although the
available studies show encouraging activity of single-agent
quizartinib, others have reported emerging mechanisms of
resistance to quizartinib [67, 68] and indicate the need for
FLT3 inhibitors with activity against resistance-conferring
point mutant forms of FLT3.
Crenolanib
Crenolanib besylate (CP-868-596) is a potent orally bioa-
vailable type 1 FLT3 TKI with activity against FLT3-ITD
and resistance-conferring FLT3-D835 TKD mutants [69]. A
phase II study of crenolanib given to 38 relapsed/refractory
patients (FLT3 TKI-naive: 13 patients; progressed on prior
FLT3 TKI: 21 patients) showed an overall response rate of
47% at a median follow-up time of 14 weeks [70]. Com-
monly reported AEs included nausea and vomiting, and
elevated liver enzymes [70, 71]. Crenolanib is also under
investigation as maintenance therapy in AML patients with
FLT3 mutations who have achieved CR after alloHCT
(NCT02400255). In this phase II trial, crenolanib is given to
a cohort of patients who achieved CR prior to alloHCT and
to a second cohort of patients who underwent alloHCT with
incomplete recovery but with ≤ 10% bone marrow blasts.
Maintenance therapy starts between days 45 to 90 after
HCT and for up to 2 years.
Gilteritinib
Gilteritinib (ASP2215) is a novel small molecule with
potent inhibitory activity against both FLT3-ITD and FLT3-
TKD mutations. Like crenolanib, gilteritinib is active
against most resistance-conferring point mutant forms of
FLT3, speciﬁcally the kinase domain mutations at residue
D835 and the gatekeeper mutation at residue F691 [67].
Early phase I/II trials showed gilteritinib to be well-tolerated
and have highly potent antileukemic activity in patients
with heavily pretreated relapsed/refractory AML regardless
of prior TKI treatment, and a current randomized phase III
trial is analyzing the value of gilteritinib as ﬁrst salvage
therapy in relapsed/refractory AML patients with FLT3
mutation [72–74]. Owing to its minimal side-effects and
potent inhibition of FLT3 in vivo, the Blood and Marrow
Transplant Clinical Trials Network (BMT CTN) is con-
ducting an international, randomized, double-blind,
placebo-controlled phase III trial to evaluate the potential
beneﬁt of maintenance therapy with gilteritinib vs. placebo
following transplant for patients with FLT3-ITD AML in
ﬁrst morphologic CR undergoing alloHCT (NCT02927262
and NCT02997202). Stratiﬁcation of participants is based
on the conditioning regimen intensity, time from trans-
plantation to randomization, and the presence or absence of
MRD from the pre-registration bone marrow aspirate.
Patients randomized to gilteritinib will receive a dose of
120 mg and all participants will continue maintenance
therapy for 2 years. The primary study objective is to
compare RFS between the two arms. A signiﬁcant com-
ponent of this study will be the use of a next-generation
sequencing (NGS) assay to assess pre-transplant and
monitor post-transplant MRD status by detection of FLT3-
ITD. Correlation between MRD status and clinical out-
comes will be necessary to validate the use of a NGS
platform for monitoring of MRD and furthermore, may
allow for the design of future clinical trials in FLT3-ITD
AML using MRD as an endpoint.
Cellular and targeted immunotherapies
Cellular therapies to enhance the GVL effect are currently
under evaluation and have the potential to treat MRD and
prevent recurrence of AML. DLI has become one standard
therapeutic approach to treat AML/MDS relapse following
alloHCT, however, its efﬁcacy and toxicity varies across
studies. Therefore, the use of DLI as a prophylactic and
preemptive intervention to harness the GVL effect prior to
relapse has been more recently explored. In a prospective
study of 75 patients with high-risk AML/MDS in which
sequential DLI was given to patients after day + 120 of RIC
alloHCT and who were off immunosuppression and were
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free of GVHD, outcomes compared favorably with pre-
viously reported results following standard conditioning,
with 2-year OS and leukemia-free survival of 42% and
40%, respectively [75]. In another retrospective analysis of
long-term outcomes following prophylactic or preemptive
DLI after RIC alloHCT for high-risk AML, OS at 7 years
after transplant was 67% as compared with 31% in the
control group (P < 0.001) [76]. In a prospective phase II
study incorporating maintenance therapy combining azaci-
tadine and DLI following myeloablative or RIC alloHCT
(VIDAZA-DLI) for the prevention of relapse in high-risk
AML/MDS, preliminary data showed a cumulative inci-
dence of relapse at 3 years of 28% and 3-year OS of 66%.
Together, the data suggest that either prophylactic or pre-
emptive DLI may have a role in the prevention of AML/
MDS relapse, however, further investigation in regards to
timing, dosing, product manipulation, and co-administration
with other agents is required [77].
Adoptive cell therapy using haploidentical natural killer
(NK) cell enrichment and adoptive transfer have resulted in
AML remissions [78, 79]. Genetically engineered antigen-
speciﬁc T cells targeting AML-speciﬁc antigens such as
Wilms tumor-1 are under active investigation [80]. Other
candidate antigens for construction of chimeric antigen
receptor T cells include CD123 [81], CD33 [82], and folate
receptor β [83]. Targeted immunotherapeutic approaches
including monoclonal antibodies directed against AML
antigenic targets (i.e., CD33, CD123, CLEC12A), immune
checkpoint inhibitors against PD-1 and CTLA4, and bis-
peciﬁc T-cell engagers are currently in early clinical trials
[84]. At last, the contribution of donor-derived B cells that
produce cytotoxic antibodies directed against AML cell
surface antigens may contribute to the GVL effect and
antitumor responses [85].
Perspectives
Signiﬁcant progress in the understanding of the key mole-
cular, epigenetic, metabolic, and immunological processes
in AML has led to novel and broad array of therapies for the
treatment of AML. In addition to epigenetic modiﬁers and
FLT3 inhibitors, other drugs such as liposomal cytarabine-
daunorubicin (CXP-351), CD33+-speciﬁc antibody-toxin
conjugate (gemtuzumab ozogamicin, vadastuximab
talirine), bcl-2 inhibitor (venetoclax), and XPO1 inhibitor
(selinexor) show promise for treatment efﬁcacy in patients
with newly diagnosed or relapsed/refractory AML and thus
provide rationale for investigation in the post-transplant
period. Recently, the IDH2 inhibitor, enasidenib, was FDA-
approved for the treatment of adult patients with relapsed/
refractory AML with an IDH2 mutation and potentially may
be appealing for the post-transplant setting given its activity
and tolerability. In addition, ivosidenib, a ﬁrst-in-class, oral,
targeted inhibitor of mutant IDH, has also shown promising
activity and safety in a phase I study of patients with IDH1-
mutated relapsed/refractory AML. Just as importantly as
clinical activity, however, potential drug-drug interactions,
risk of acute/chronic GVHD, and side-effects of main-
tenance agents such as cytopenias and intolerable gastro-
intestinal symptoms must also be accounted for as these
toxicities limit quality-of-life (QoL) and impede the max-
imal beneﬁt of a drug. As such, QoL metrics and other
patient-reported outcomes should be increasingly included
in AML maintenance trials as these endpoints are infor-
mative in determining the success of a therapy.
The availability of more sensitive assays for MRD has
implications in treatment decisions, response evaluations,
and MRD status after therapy potentially represents a new
endpoint in clinical research studies. However, current
MRD platforms vary between institutions and standardiza-
tion of assays is lacking. As new agents and technologies
continue to develop, further questions on post-transplant
strategies to prevent relapse need to be answered and
include determining appropriate patient risk groups war-
ranting maintenance vs. preemptive vs. no treatment fol-
lowing transplantation, and optimal timing and duration of
treatment. The optimal approach to treating patients at high-
risk of AML relapse following transplant remains con-
troversial and owing to the lack of phase III clinical data,
there is insufﬁcient evidence to support the routine use of
post-transplant maintenance therapies. We strongly support
the development of prospective, randomized studies to
determine the clinical efﬁcacy of available therapies.
Although early phase studies demonstrate safety and toler-
ability of various approaches in the post-transplantation
period, the results of ongoing or planned prospective ran-
domized studies are required to determine the clinical efﬁ-
cacy needed to move this approach from experimental to
standard-of care.
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